**Supplementary Table 1. Parameters of one-way sensitivity analysis.**

|  |  |  |  |
| --- | --- | --- | --- |
| Input | MIN | MAX | Source |
| Waning rate | 0% | 10% | Assumption |
| Discount rates (costs) | 0% | 5% | Assumption |
| Discount rates (utilities) | 0% | 5% | Assumption |
| Vaccine efficacy duration | 7,5 years (HZ), 5 years (PHN) | 20 years | Assumption |
| Vaccine efficacy HZ (age cohort split)60-6970-79 | Lower limit of 95%56%28% | Upper limit of 95%71%52% | [5] |
| Vaccine efficacy PHN(age cohort split)60-6970-79 | Lower limit of 95%20.4%43.3% | Upper limit of 95%86.7%81.3% | [5] |
| Utilities HZ (pain split)No painMild painModerate painSevere pain | 0.860.730.600.47 | 0.860.770.680.55 | Min [20]Max [23] |
| Utilities PHN (pain split)Mild painModerate painSevere pain | 0.730.600.47 | 0.770.680.55  | Min [20]Max [23] |
| HZ Incidence  | 0.0351% | 0.0720% | [4] |
| PHN Incidence  | 14.30% | 24.50% | [17] |
| Vaccine price | € 80 | € 120 | Assumption |
| Total costs | 20% decrease | 20% increase | Assumption |
| Method for utilities | Additive | Multiplicative | [9] |